Abstract: Mixtures of three types of linear, branched or cyclic phosphates are useful flame retardants, especially for thermoplastic resins or as functional additives in polymer matrices.

Abstract: Mixtures of three types of linear, branched or cyclic phosphates are useful flame retardants, especially for thermoplastic resins or as functional additives in polymer matrices.

Abstract: A method for making a plant growth regulator includes the step of reacting vinyl chloride with a phosphorous reagent.

Abstract: The invention is directed to a phosphonate composition having flame retardant properties. The phosphonate composition of the invention has the general formula: wherein R1 and R2 are independently C1–C4 alkyl, R3 is H or C1–C4 alkyl, and R4 is linear or branched C9–C22 alkyl, C9–C22 cycloalkyl, C9–C22 aryl or C9–C22 aralkyl and n=0 or 1. The invention is also directed to a method of producing the phosphonate composition having flame retardant properties.

Abstract: A process of producing cyanoalkyl tetraalkylphosphordiamidites at least substantially free of amine hydrohalide with improved storage stability.

Abstract: The invention is directed to a phosphonate composition having flame retardant properties. The phosphonate composition of the invention has the general formula: wherein R1 and R2 are independently C1-C4 alkyl, R3 is H or C1-C4 alkyl, and R4 is linear or branched C9-C22 alkyl, C9-C22 cycloalkyl, C9-C22 aryl or C9-C22 aralkyl and n=0 or 1. The invention is also directed to a method of producing the phosphonate composition having flame retardant properties.

Abstract: A process of producing cyanoalkyl tetraalkylphosphordiamidites at least substantially free of amine hydrohalide with improved storage stability.

Abstract: Methods of treating chronic arthritis and osteoporosis which utilize both known and novel compounds which would fall under the general formula:(HO)p--A--[--OS(O).sub.2 NR.sup.1 R.sup.2 ].sub.zwherein A encompasses a wide range of values including but not limited to aryl, loweralkyl, cycloalkyl, and carbohydrates including sucrose and fructose; p is equal to the number of unreacted hydroxy groups contained on the molecule and may be zero; z is the number of --OS(O).sub.2 NR.sup.1 R.sup.2 groups and is always at least one; R.sup.1 and R.sup.2 are selected from hydrogen, loweralkyl, carboxy and the like; a novel process for preparing the compounds is provided wherein an appropriate sulfamic acid aryl ester is reacted with a hydroxy substituted A radical which may or may not contain thereon protected carboxyl, amino or hydroxy substituents, in an aprotic solvent containing a tertiary amine base. Pharmaceutical compositions for the treatment of chronic arthritis and osteoporosis are also provided.

Abstract: Methods of treating chronic arthritis and osteoporosis which utilize both known and novel compounds which would fall under the general formula:(HO)p--A--[--OS(O).sub.2 NR.sup.1 R.sup.2 ].sub.zwherein A encompasses a wide range of values including but not limited to aryl, loweralkyl, cycloalkyl, and carbohydrates including sucrose and fructose; p is equal to the number of unreacted hydroxy groups contained on the molecule and may be zero; z is the number of --OS(O).sub.2 NR.sup.1 R.sup.2 groups and is always at least one; R.sup.1 and R.sup.2 are selected from hydrogen, loweralkyl, carboxy and the like; a novel process for preparing the compounds is provided wherein an appropriate sulfamic acid aryl ester is reacted with a hydroxy substituted A radical which may or may not contain thereon protected carboxyl, amino or hydroxy substituents, in an aprotic solvent containing a tertiary amine base. Pharmaceutical compositions for the treatment of chronic arthritis and osteoporosis are also provided.

Abstract: Sulfamate esters of the formula(HO).sub.p --A--[OSO.sub.2 NR.sup.1 R.sup.2 ].sub.zwhere A is aryloxyalkyl, p is the number of unreacted hydroxy groups present on the alkyl moiety and may be zero, z is the number of --OS(O).sub.2 NR.sup.1 R.sup.2 groups attached to carbons of the alkyl moiety and is always at least one; R.sup.1 and R.sup.2 are selected from hydrogen, loweralkyl, carboxy, and the like are useful in treating glaucoma.

Abstract: A novel process is described for preparing azetidine and 2 or 3 methyl and ethyl azetidine free bases by reacting primary arylmethylamine having suitable bulk providing substituents attached to the methyl carbon and an appropriate propane derivative having leaving groups in the one and three position in hot organic solvent containing a non-nucleophilic base and an amount of water sufficient to promote azetidine ring formation to give N-protected-azetidines and deprotecting by hydrogenolysis under acidic conditions to give an acid salt of the azetidines and thereafter flashing off vaporized azetidine from a hot, agitated strong base solution or slurry and condensing to give the liquid azetidine free bases.

Abstract: A novel process is described for preparing azetidine and 2 or 3 methyl and ethyl azetidine free bases by reacting primary arylmethylamine having suitable bulk providing substituents attached to the methyl carbon and an appropriate propane derivative having leaving groups in the one and three position in hot organic solvent containing a non-nucleophilic base and an amount of water sufficient to promote azetidine ring formation to give N-protected-azetidines and deprotecting by hydrogenolysis under acidic conditions to give an acid salt of the azetidines and thereafter flashing off vaporized azetidine from a hot, agitated strong base solution or slurry and condensing to give the liquid azetidine free bases.

Abstract: Novel 2-amino-3-(alkylthiobenzoyl)phenylacetic acids, esters and metal salts have the formula: ##STR1## wherein R is hydrogen or lower alkyl, R.sup.1 is hydrogen, lower alkyl or pharmaceutically acceptable metal cation, R.sup.2 is hydrogen, halogen, lower alkyl or lower alkoxy, Am is primary amino (--NH.sub.2), methylamino or dimethylamino. The compounds have anti-inflammatory activity; have effective analgesic activity, and inhibit blood platelet aggregation.

Abstract: Novel 2-amino-3-benzoyl-phenylacetamides are provided having the formula: ##STR1## wherein R represents hydrogen or lower alkyl, R.sup.1 and R.sup.2 represent hydrogen, lower alkyl, cycloalkyl, phenyl and phenyl substituted by lower alkyl, lower alkoxy, halogen, nitro and trifluoromethyl, and R.sup.1 and R.sup.2 when taken together with the adjacent nitrogen may form a heterocyclic residue; X represents hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; Y represents hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, lower alkylthio, lower alkyloxythio or lower alkyldioxythio; Am is primary amino (--NH.sub.2), methylamino or dimethylamino, and n is 1 to 3 inclusive. The compounds exhibit anti-inflammatory, antipyretic, anti-blood platelet aggregation and analgetic pharmacological activities.

Abstract: Cis and trans 3-amino-4-hydroxypyrrolidines and derivatives thereof are disclosed having the formula: ##STR1## wherein R.sub.1 is hydrogen, loweralkyl or phenylcarbonyl; R.sub.2 is hydrogen, loweralkyl, lowercycloalkyl, phenyl or phenylloweralkyl; R.sub.3 is hydrogen, loweralkyl, phenylloweralkyl, phenylcarbonyl, diphenylmethyl, 5-yl-10,11-dihydro-5H-dibenzo[a,d]cycloheptene or naphthylcarbonyl; R.sub.4 is hydrogen, loweralkyl, phenylloweralkyl or lowercycloalkyl; phenyl is optionally substituted and acid addition salts thereof. The compounds have antidepressant activity and methods and pharmaceutical compositions for use thereof are disclosed.